Lexicon Pharmaceuticals Collects Third $10M Milestone from Novo Nordisk for Obesity Drug LX9851 — Lexicon Pharmaceuticals, Inc.

Event summary

Lexicon Pharmaceuticals earned a third $10 million milestone payment from Novo Nordisk in 2026 for progress in Phase 1 trials of LX9851, an obesity treatment.
The payment is part of a $1 billion potential deal signed in 2025, with Lexicon eligible for royalties on future net sales.
Phase 1 trials, initiated in March 2026, are investigating safety and efficacy in overweight or obese adults and are expected to conclude in Q1 2027.
LX9851 is a first-in-class oral small molecule inhibitor targeting ACSL5, showing promise in preclinical studies when combined with semaglutide.

The big picture

Lexicon's milestone payment underscores the strategic importance of its collaboration with Novo Nordisk, a leader in obesity and metabolic disorder treatments. The deal reflects growing industry focus on novel mechanisms for weight management, particularly as global obesity rates rise. Lexicon stands to benefit from Novo Nordisk's commercialization expertise, but must navigate competitive pressures in the space.

What we're watching

Clinical Progress: The pace at which LX9851 advances through Phase 1 trials will determine Novo Nordisk's development timeline and Lexicon's milestone earnings.
Commercial Potential: Whether LX9851 can differentiate itself in the competitive obesity drug market, particularly alongside Novo Nordisk's existing treatments.
Financial Upside: How Lexicon leverages the $1 billion potential deal to strengthen its financial position and fund other pipeline candidates.